Shareholder Alert: Robbins LLP Reminds Investors that NRx Pharmaceuticals, Inc. (NRXP) is Being Sued for Misleading Shareholders
The Californer/10173745

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) securities between June 1, 2021 and November 4, 2021, for violations of the Securities Exchange Act of 1934. NRx is a clinical-stage pharmaceutical company that develops therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The Company's products include, among others, ZYESAMI, an investigational pre-commercial drug for COVID-19 related respiratory failure.

If you suffered a loss due to NRx Pharmaceuticals, Inc.'s misconduct, click here.

More on The Californer

• Hundreds of new homes for veterans are coming to California through voter-approved Prop 1 funding
• LSC Destruction Launches Cutting-Edge Cryptocurrency Scanning to Hard Drive Destruction Services
• California highlights earthquake preparedness for Great ShakeOut Day
• DALPS Announces Global Airdrop to Reward Users and Expand Its Offers Marketplace
• Governor Newsom expands response arsenal with new emergency services facility in Southern California

NRx Pharmaceutical, Inc. (NRXP) Misled Investors Regarding the EAU Status of its Drug Candidate

According to the complaint, in June 2021, NRx announced it had filed an application with the U.S. Food and Drug Administration ("FDA") requesting Emergency Use Authorization ("EUA") for ZYESAMI to treat critically ill COVID-19 patients suffering with respiratory failure. However, defendants failed to disclose that the ZYESAMI EUA application contained insufficient data regarding the potential benefits and risks of the drug and therefore, the FDA was unlikely to approve the ZYESAMI EUA application in its present form.

On November 4, 2021, NRx issued a press release announc[ing] that the [FDA] has declined to issue an [EUA] for ZYESAMI® (aviptadil). The FDA stated that it was unable to issue the EUA at this time due to insufficient data regarding the known and potential benefits of the medicine and the known and potential risks of ZYESAMI in patients suffering from Critical COVID-19 with respiratory failure." On this news, NRx's stock price fell $2.27 per share or over 25%, to close at $6.65 per share on November 5, 2021.

If you purchased shares of NRx Pharmaceutical, Inc. (NRXP) between June 1, 2021 and November 4, 2021, you have until March 21, 2022, to ask the court to appoint you lead plaintiff for the class.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

More on The Californer

• ALYXX Features on Oceans In Silhouette "Under My Skin" Single
• $150 Million Financing Initiates N A S D A Q's First Tether Gold Treasury Combining the Stability of Physical Gold with Blockchain $AURE
• DALPS Launches Marketplace Allowing Businesses to Trade Offers Like Stocks
• California: Governor Newsom announces affordable CalRx® insulin, $11 a pen, will soon be available for purchase
• Cardirun Foldable Treadmill for Home and Office, 10% Incline, 320 LBS Weight Capacity

Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against NRx Pharmaceutical, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

---

Show All News | Report Violation